Neoplasms

Heart and Blood Diseases

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Symptoms and General Pathology

Skin and Connective Tissue Diseases

Substance Related Disorders

Wounds and Injuries

Rare Diseases

Multiple Myeloma

Neoplasms, Plasma Cell

Neoplasm Metastasis

Breast Neoplasms

Lymphoma

Leukemia

Drug-Related Side Effects and Adverse Reactions

Cardiotoxicity

Chemically-Induced Disorders

Radiation Injuries

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Immunoproliferative Disorders

Hemostatic Disorders

Blood Coagulation Disorders

Vascular Diseases

Paraproteinemias

Blood Protein Disorders

Hematologic Diseases

Hemorrhagic Disorders

Heart Diseases

Breast Diseases

Skin Diseases

Lymphosarcoma

Chronic Graft Versus Host Disease

Intensive cardiovascular monitoring focused on prevention and early diagnosis and treatment of cardiotoxicity based in cardio-onco-hematology teams involved in cancer patient care.

Current clinical practice: cardiac care is based on the onco-hematologist criteria.

Schedule of visits: Evaluation before starting chemotherapy, at three and six months and annually for five years (eight visits: baseline, 3rd and 6th month, 1st, 2nd, 3rd, 4th and 5th years).

Assessment protocol: Anamnesis and physical examination; EKG; Echocardiogram; Biomarkers (troponin and natriuretic peptide); Structured counselling on healthy cardiac practices; Treatment optimization of cardiovascular risk factors and heart diseases; Quality of life (ECOG Performance status and Minnesota questionnaires); Interaction and management of patient care by the cardio-onco-hematology team. Moreover, cardiac MRI in centers participating in the CARTIER-MR sub-study.

Intensive cardiovascular monitoring

Schedule of visits: Evaluation before starting chemotherapy, at three and six months and annually for five years (eight visits: baseline, 3rd and 6th month, 1st, 2nd, 3rd, 4th and 5th years).

Assessment protocol: Anamnesis and physical examination; ECOG Performance status; cardiac patient care based on the onco-hematologist criteria

No intervention

Pedro L Sánchez, Ph. D.

Ana Martín-García, Ph. D.

Pilar Mazón-Ramos, MD

Sonia Velasco, MD

Ignacio Ferreira-González, MD

Dolores Mesa, MD

Fernando Alfonso-Manterola

Fernando Alfonso-Manterola, Md

Eduardo Zatarain-Nicolás

Eduardo Zatarain-Nicolás, MD

Ana Pardo-Sanz, MD

Luis F Navarro-del-Amo, MD

Carmen Jiménez-López-Guarch, MD

Cristina Mitroi, MD

Juan J Gómez-Doblas

Juan J Gómez-Doblas, MD

Gonzalo Baron-Esquivias

Gonzalo Baron-Esquivias, MD

Marina Revilla-Martínez, MD

The CARTIER study is a randomized, multicenter, open-label clinical trial comparing, in elderly patients with cancer under anti-tumoral treatment, two different cardiotoxicity prevention strategies: primary (intensive cardiovascular monitoring focused on prevention and early diagnosis and treatment of cardiotoxicity based in cardio-onco-hematology teams involved in cancer patient care) vs. secondary (current clinical practice where intensive cardiovascular monitoring is not routinely performed and cardiotoxicity patient care is based on the onco-hematologist criteria).

The primary endpoint is to determine whether this primary prevention englobing cardiovascular monitoring plus intensive multidisciplinary management is superior to the current clinical practice in reducing all cause mortality.

Other secondary objectives of the study are to analyze the impact of this intensive cardiovascular monitoring strategy on the incidence of cardiovascular mortality, oncological mortality, hospitalization and/or urgent care due to cardiovascular complications, hospitalization and/or urgent oncological care due to cancer complications, tumor progression and cost-effectiveness analysis.

A total of 514 patients ≥ 65 years old diagnosed with any of the following onco-hematological cancers, colon, breast, lymphoma, chronic lymphoma leukemia, chronic myeloid leukemia or myeloma, undergoing standardized anti-tumoral treatment, will be recruited.

The incidence of primary and secondary outcomes will be measured at 2 and 5 years

Randomized, multicenter, open-label clinical trial comparing, in elderly patient with cancer under anti-tumoral treatment, two different cardiotoxicity prevention strategies

Cardiovascular Prevention Strategies in Elderly Patients With Cancer (CARTIER Clinical Trial)

Cardiotoxicity in the Elderly. Comparative Clinical Trial Between Primary Versus Secondary Cardiovascular Prevention Strategies

Cumulative incidence of all-cause mortality

Cumulative incidence of oncological mortality

Cumulative incidence of cardiovascular mortality

Cumulative incidence of hospitalization and/or emergency care for cardiovascular cause

Spots Global Cancer Trial Database for secondary prevention.